Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

6 recruiting

Enrollment Performance

Analytics

N/A

7(77.8%)

Phase 2

2(22.2%)

9Total

N/A(7)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06282588Phase 2Recruiting

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

Role: lead

NCT06739655Not ApplicableRecruiting

Preoperative Radiation Therapy and Immediate Breast Reconstruction

Role: lead

NCT07146074Not ApplicableRecruiting

Early Radiotherapy Versus Observation for High-risk Asymptomatic or Minimally Symptomatic Bone Metastases

Role: lead

NCT06691425Not ApplicableRecruiting

Stereotactic Body Radiation Therapy for Inoperable Non-metastasized Pancreatic Adenocarcinoma

Role: lead

NCT06613295Not ApplicableRecruiting

Separation Surgery Followed by Stereotactic Ablative Body Radiotherapy (SABR) Versus SABR Alone for Spinal Metastases

Role: lead

NCT03486431Not ApplicableCompleted

A Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy for Non-spine Bone & Lymph Node Oligometastates

Role: lead

NCT03831243Not ApplicableCompleted

A Trial to Improve Quality of Life With Stereotactic Body Radiotherapy for Patients With Painful Bone Metastases

Role: lead

NCT03899077Phase 2Recruiting

Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP

Role: lead

NCT05011500Not ApplicableUnknown

Masks Against Surface-Scanning for Radiation Therapy Immobilisation in Head and Neck Cancer (MASSC)

Role: lead

All 9 trials loaded